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BACKGROUND
Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-
cell transplantation; not all patients have a response to standard glucocorticoid treat-
ment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, 
showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.
METHODS
We conducted a multicenter, randomized, open-label, phase 3 trial comparing the ef-
ficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator’s choice 
of therapy from a list of nine commonly used options (control) in patients 12 years of 
age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell 
transplantation. The primary end point was overall response (complete response or 
partial response) at day 28. The key secondary end point was durable overall response 
at day 56.
RESULTS
A total of 309 patients underwent randomization; 154 patients were assigned to 
the ruxolitinib group and 155 to the control group. Overall response at day 28 was 
higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 
39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). 
Durable overall response at day 56 was higher in the ruxolitinib group than in the 
control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; 
P<0.001). The estimated cumulative incidence of loss of response at 6 months was 
10% in the ruxolitinib group and 39% in the control group. The median failure-free 
survival was considerably longer with ruxolitinib than with control (5.0 months vs. 
1.0 month; hazard ratio for relapse or progression of hematologic disease, non–
relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 
95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib 
group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 
0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia 
(in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the 
control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalo-
virus infection (in 39 [26%] and 31 [21%]).
CONCLUSIONS
Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a 
higher incidence of thrombocytopenia, the most frequent toxic effect, than that ob-
served with control therapy. (Funded by Novartis; REACH2 ClinicalTrials.gov num-
ber, NCT02913261.)
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The incidence of allogeneic stem-cell transplantation is increasing world-wide1,2 owing to more widespread use of 
reduced-intensity conditioning regimens and ac-
cess to alternative stem-cell sources.2,3 A major 
limitation of allogeneic stem-cell transplantation 
is acute graft-versus-host disease (GVHD), a con-
dition in which donor T cells attack host tissue, 
affecting multiple organs, particularly the skin, 
liver, and gastrointestinal tract.4,5 The pathogen-
esis of GVHD is also influenced by the release of 
danger-associated molecular patterns6 and tis-
sue damage caused by neutrophil granulocytes.7 
Despite standard prophylaxis, GVHD develops in 
approximately 50% of recipients of allogeneic 
stem-cell transplantation.5,8,9 GVHD is a substan-
tial cause of death in patients undergoing allo-
geneic stem-cell transplantation.10-13 Standard 
first-line treatment is systemic, high-dose gluco-
corticoids4,9; however, response ranges from ap-
proximately 60% in patients with grade II dis-
ease to 30 to 40% in patients with grade IV 
disease.13,14 Glucocorticoids are also associated 
with clinically significant side effects, which can 
lower patients’ quality of life and render patients 
susceptible to infection.15 For patients with glu-
cocorticoid-refractory acute GVHD, no consensus 
exists regarding treatment, and outcomes remain 
poor.4,5,9,13 Despite numerous phase 2 trials and 
two previous randomized, phase 3 trials, no treat-
ment has shown superiority over other treatments, 
and, with the exception of ruxolitinib, no new 
drugs have been approved either as first-line or 
second-line treatment for acute GVHD in the past 
30 years.9,12,16,17
The Janus kinase (JAK) and signal transducers 
and activators of transcription (STAT) signaling 
pathways play an important role in immune-cell 
activation and tissue inflammation during acute 
GVHD,18-20 including the activity of dendritic cells21 
and neutrophil granulocytes.22 Tissue damage that 
is associated with acute GVHD is driven by inflam-
matory cytokines, the effects of which are medi-
ated in part by JAKs.5,23 Ruxolitinib is an oral selec-
tive inhibitor of JAK1 and JAK28 that reduces the 
incidence and severity of GVHD in vivo while 
preserving graft-versus-leukemia effects in pre-
clinical models.18-20 In a single-group, phase 2 trial 
of ruxolitinib in patients with glucocorticoid-
refractory grade II to IV acute GVHD (REACH1), 
54.9% of the patients had a response at day 28.24 
Here we report the results of a randomized, phase 
3 trial (REACH2) that was conducted to compare 
the efficacy and safety of ruxolitinib with the 
investigator’s choice of therapy from a list of 
nine commonly used options (“best available 




The trial was designed and data were analyzed 
by the sponsor (Novartis) in collaboration with 
the trial steering committee. Writing and edito-
rial assistance was provided by Excerpta Medica, 
with funding by the sponsor. All the authors 
vouch for the accuracy and completeness of the 
data and for the fidelity of the trial to the proto-
col (available with the full text of this article at 
NEJM.org).
The trial was designed and conducted in ac-
cordance with the guidelines for Good Clinical 
Practice of the International Council for Harmoni-
sation, with applicable local regulations, and with 
the principles of the Declaration of Helsinki. The 
protocol was approved at each participating cen-
ter by the relevant institutional review board, in-
dependent ethics committee, or research ethics 
board.
Patients
Eligible patients were at least 12 years of age and 
were recipients of allogeneic stem-cell transplan-
tation (any donor source, any stem-cell source) 
who had grade II to IV glucocorticoid-refractory 
acute GVHD that involved the use of systemic im-
munosuppressive therapy (see the Supplementary 
Methods section in the Supplementary Appendix, 
available at NEJM.org).25 Glucocorticoid-refractory 
disease was defined as disease progression on the 
basis of organ assessment after at least 3 days of 
high-dose systemic glucocorticoid therapy, with 
or without calcineurin inhibitors; a lack of re-
sponse (absence of partial response or better) after 
7 days; or treatment failure during glucocorticoid 
taper (i.e., an increase in the methylprednisolone 
dose to ≥2 mg per kilogram of body weight per 
day [or equivalent ≥2.5 mg per kilogram per day 
of prednisone] or an inability to taper the dose 
to <0.5 mg per kilogram per day of methylpred-
nisolone [or equivalent <0.6 mg per kilogram per 
day of prednisone] for a minimum of 7 days). 
Myeloid and platelet engraftment, defined as an 
absolute neutrophil count of more than 1000 cells 
per cubic millimeter and a platelet count of at 
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least 20,000 cells per cubic millimeter, was con-
firmed within 48 hours before the initiation of 
treatment. Patients were excluded if their tumor 
had relapsed after any allogeneic stem-cell trans-
plantation in the previous 6 months; if they had 
a relapsed primary cancer after undergoing alloge-
neic stem-cell transplantation; if they had received 
more than one previous treatment for glucocor-
ticoid-refractory acute GVHD; if they had an ac-
tive, uncontrolled infection; or if they had received 
JAK inhibitor therapy for any indication after the 
initiation of allogeneic stem-cell transplantation 
conditioning.
Trial Design
REACH2 was a multicenter, randomized, open-
label, phase 3 trial. Patients (or their guardians) 
provided written informed consent, and patients 
were then assessed for eligibility during a maxi-
mum 28-day screening period after the receipt of 
first-line glucocorticoid treatment. Eligible patients 
were randomly assigned in a 1:1 ratio to receive 
either ruxolitinib or the investigator’s choice of 
therapy from a list of nine commonly used options 
(control; see below) for up to 24 weeks. Random-
ization was stratified according to the baseline 
grade of acute GVHD (II vs. III vs. IV).
Ruxolitinib was given orally at a dose of 10 mg 
twice daily. Guidance was provided for dose modi-
fications for adverse events (see the Supplementary 
Methods section). Tapering of ruxolitinib was per-
mitted after day 56 in patients who had a response.
The type of control therapy was chosen by the 
investigator at the time of randomization from 
the following options: antithymocyte globulin, 
extracorporeal photopheresis, mesenchymal stro-
mal cells, low-dose methotrexate, mycophenolate 
mofetil, mammalian target of rapamycin (mTOR) 
inhibitor (everolimus or sirolimus), etanercept, or 
infliximab. Crossover from control therapy to 
ruxolitinib therapy was permitted if patients did 
not have a response at day 28 or if they had a loss 
of response thereafter and received additional 
systemic therapy and did not have signs of chron-
ic GVHD. Standard supportive therapy (including 
growth factors, anti-infective medication, transfu-
sion support, and other standard supportive care 
measures) was allowed in both treatment groups 
in addition to the continued use of calcineurin in-
hibitors and glucocorticoids. Owing to the in-
creased risk of bleeding after allogeneic stem-cell 
transplantation, concomitant treatment with 
aspirin, nonsteroidal antiinflammatory drugs, 
heparin, warfarin, or related medications was 
prohibited.
Patient visits occurred weekly from day 1 to 
day 56 and then every 4 weeks from day 56 
through week 24, unless a prolonged tapering 
period was deemed to be necessary. A safety fol-
low-up visit occurred 30 days after the last dose of 
trial treatment. Long-term follow-up visits were 
scheduled at months 6, 9, 12, 18, and 24 after 
randomization in order to collect data on survival, 
progression, and safety outcomes.
End Points and Assessments
The primary end point was overall response at 
day 28, which was defined as the proportion of 
patients who had a complete response or partial 
response as compared with baseline organ stag-
ing25 without the use of additional systemic therapy 
for acute GVHD (see the Supplementary Methods 
section). We chose day 28 on the basis of previous 
data on end points in patients with acute GVHD.26
The key secondary end point was durable over-
all response at day 56, which was defined as the 
proportion of patients in each treatment group 
who had response at day 28 that was maintained 
at day 56. Other secondary end points included the 
duration of response (time from first response to 
acute GVHD progression or the addition of new 
systemic therapy for acute GVHD; competing risks 
were the onset of chronic GVHD or death without 
progression of acute GVHD), best overall response 
(proportion of patients with a complete or partial 
response at any time up to and including day 28 
and before the start of additional systemic thera-
py for acute GVHD), failure-free survival (time 
from randomization to relapse or progression of 
hematologic disease, non–relapse-related death, 
or the addition of new systemic therapy for acute 
GVHD; the competing risk was the onset of chron-
ic GVHD), overall survival (time from randomiza-
tion to death due to any cause), and cumulative 
glucocorticoid use until day 56. The cumulative 
incidence of the following events was also calcu-
lated: non–relapse-related death (time from ran-
domization to death not preceded by hematologic 
disease relapse or progression; the competing 
event was relapse or progression of hematologic 
disease) and relapse or progression of cancer (time 
from randomization to relapse or progression of 
hematologic cancer; the competing risk was non–
relapse-related death).
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Safety was assessed by monitoring the fre-
quency, duration, and severity of adverse events, 
including the occurrence of any infection or sec-
ond primary cancer, by means of routine physical 
examination and laboratory assessments. Ad-
verse events were assessed according to the Com-
mon Terminology Criteria for Adverse Events, ver-
sion 4.03.
Statistical Analysis
We calculated that a target of 308 patients under-
going randomization would provide the trial with 
90% power to test the primary end point (response 
at day 28) and approximately 90% power to test 
the secondary end point (response persisting at 
day 56). The full analysis set included all the pa-
tients who underwent randomization. The safety 
analysis set included all the patients who received 
at least one dose of trial treatment.
For the primary end point and key secondary 
end point, outcomes were summarized according 
to treatment group with the use of descriptive sta-
tistics with a two-sided exact binomial 95% confi-
dence interval.27 The Cochran–Mantel–Haenszel 
chi-square test, stratified according to the ran-
domization stratification factor (i.e., acute GVHD 
of grade II vs. III vs. IV), was used to compare 
end points between the two treatment groups at 
a two-sided significance level of 5%. (The trial 
was designed to test the hypothesis that the 
overall response at day 28 with ruxolitinib ther-
apy would be superior to the overall response at 
day 28 with control therapy, in alignment with the 
reported clinical efficacy of ruxolitinib in patients 
with glucocorticoid-refractory acute GVHD; the 
protocol prespecified the reporting of one-sided 
P values, but, in accordance with Journal policy, 
two-sided P values are reported). P values, odds 
ratios, and 95% Wald confidence limits were cal-
culated.
A hierarchical testing strategy was used to 
control overall type I error in which the durable 
response at day 56 was formally tested and inter-
preted only if the primary analysis of response at 
day 28 was significant. The familywise alpha level 
was controlled at 0.025 overall for the two com-
parisons (primary and key secondary end points). 
Specifically, the trial would achieve the efficacy 
objective if the primary end point of response at 
day 28 showed a significant treatment effect at a 
one-sided alpha level of 0.025 (reported at a two-
sided alpha level of 0.05). Conditional on the sig-
nificance of the primary end point, the key second-
ary end point was tested at a one-sided alpha of 
0.025 (reported at a two-sided alpha level of 0.05). 
There was no prespecified plan to control for mul-
tiple comparisons of the secondary outcome mea-
sures; 95% confidence intervals are reported, 
without P values. The 95% confidence intervals 
were not adjusted for multiple comparisons and 
should not be used to infer definitive treatment 
effects.
A cumulative-incidence curve for failure-free 
survival was prepared for each treatment group. 
Kaplan–Meier curves for failure-free survival and 
overall survival were plotted, and the hazard ratios 
were calculated, along with the 95% confidence 
intervals, with the use of a stratified Cox model. 
Further details on the statistical analysis plan are 
provided in the Supplementary Methods section.
R esult s
Patients
Between April 12, 2017, and May 30, 2019, a 
total of 309 patients from 105 treatment centers 
in 22 countries were randomly assigned to receive 
either ruxolitinib (154 patients) or control therapy 
(155) (Fig. 1). A total of 104 patients (34%) had 
grade II acute GVHD, 136 (44%) had grade III 
disease, and 62 (20%) had grade IV disease; the 
distribution of patients according to acute GVHD 
grade was similar in the two treatment groups. 
(Five patients [2%] had grade 0 disease, and 2 [1%] 
had grade I disease; these patients had undergone 
randomization in error and were flagged as hav-
ing a protocol deviation.) The median age of the 
patients was 54 years (range, 12 to 73), 9 patients 
were adolescents, and 59% of the patients were 
male. The baseline demographic characteristics 
and transplantation-related and disease-related 
characteristics of the patients were balanced be-
tween the two treatment groups (Table 1 and Ta-
ble S1 in the Supplementary Appendix). The most 
common initial control therapy was extracorpo-
real photopheresis, which was received by 41 of 
150 patients (27%) (Fig. S1). Of the 155 patients 
who had been assigned to the control group, 49 
(32%) crossed over to receive ruxolitinib on or after 
day 28. The median follow-up was 5.04 months 
(range, 0.03 to 24.02) among patients in the rux-
olitinib group and 3.58 months (range, 0.03 to 
23.62) among those in the control group; the 
data-cutoff date was July 25, 2019.
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Efficacy
Overall response at day 28 was significantly higher 
in the ruxolitinib group than in the control group 
(62% [96 of 154 patients] vs. 39% [61 of 155 pa-
tients]; odds ratio, 2.64; 95% confidence interval 
[CI], 1.65 to 4.22; P<0.001 by the stratified 
Cochran–Mantel–Haenszel test) (Fig. 2A). The per-
centage of patients with a complete response 
was 34% (53 patients) and 19% (30 patients), 
respectively. The percentage of patients with a 
response was highest among patients with grade 
II acute GVHD at baseline (75% [40 of 53 patients] 
in the ruxolitinib group vs. 51% [27 of 53 patients] 
in the control group) and among those with grade 
III acute GVHD (56% [40 of 71 patients] vs. 38% 
[27 of 72 patients]). However, the odds ratio for 
response with ruxolitinib as compared with con-
trol was highest among patients with grade IV 
acute GVHD at baseline (53% [16 of 30 patients] 
vs. 23% [7 of 30 patients]; odds ratio, 3.76; 95% CI, 
1.24 to 11.38) (Table S2). Improvement in the acute 
GVHD grade for skin, liver, upper gastrointestinal, 
and lower gastrointestinal involvement is shown 
for each treatment group in Figure S2. Response 
according to the chosen control therapy is shown 
in Table S3.
Durable overall response at day 56 was signifi-
cantly higher in the ruxolitinib group than in the 
control group (40% [61 patients] vs. 22% [34 pa-
tients]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; 
P<0.001) (Fig. 2B). The best overall response at 
day 28 (percentage of patients who had a com-
Figure 1. Eligibility, Randomization, and Follow-up.
A total of 310 patients with acute graft-versus-host disease (GVHD) underwent randomization, but 1 patient was ex-
cluded from all the analyses because written informed consent was not obtained. Patients in the control group were 
to receive the investigator’s choice of therapy from a list of nine commonly used options: antithymocyte globulin, 
extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, mycophenolate mofetil, mam-
malian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus), etanercept, or infliximab. Reasons for dis-
continuation of the intervention in either group were a lack of efficacy, adverse event, death, the fact that continua-
tion criteria in the protocol were not met, disease relapse, decision by the physician, decision by the patient or 
guardian, and graft loss.
309 Underwent randomization
310 Were excluded
296 Did not meet inclusion criteria
7 Died
4 Declined to participate
3 Had other reason
154 Were assigned to receive ruxolitinib
152 Received ruxolitinib
2 Did not receive ruxolitinib
155 Were assigned to receive control therapy
150 Received control therapy
5 Did not receive control therapy
49 Crossed over to ruxolitinib
on or after day 28
154 Were included in the analysis 155 Were included in the analysis
111 Discontinued intervention 132 Discontinued intervention
620 Patients were assessed for eligibility
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plete or partial response at any time up to and 
including day 28 and before the start of addi-
tional systemic therapy for acute GVHD) was 
82% (126 patients) in the ruxolitinib group and 
61% (94 patients) in the control group (odds ra-
tio, 3.07; 95% CI, 1.80 to 5.25) (Table S4). The es-
timated cumulative incidence of loss of response 
at 6 months was 10% (95% CI, 4 to 17) in the 
ruxolitinib group and 39% (95% CI, 26 to 52) in 
the control group (Fig. 3A and Table S5). By day 
56, a total of 32 patients (21%) in the ruxolitinib 
group had discontinued glucocorticoids, as com-
pared with 21 (14%) in the control group.
The median failure-free survival was signifi-
cantly longer in the ruxolitinib group than in the 
control group (5.0 months vs. 1.0 month; hazard 
ratio for relapse or progression of hematologic 
disease, non–relapse-related death, or addition of 
new systemic therapy for acute GVHD, 0.46; 
95% CI, 0.35 to 0.60) (Fig. 3B), and the cumula-
tive incidence of such events at 1 month was 
lower in the ruxolitinib group than in the con-
trol group (18% vs. 49%) and remained lower at 
all time points up to 18 months (61% vs. 82%) 
(Fig. S3 and Table S6). The cumulative incidence 
of cancer relapse or progression at 18 months was 
13% in the ruxolitinib group and 19% in the 
control group (Fig. S4 and Table S7). The cumu-
lative incidence of non–relapse-related death at 
18 months was 49% in the ruxolitinib group and 
51% in the control group (Fig. S5 and Table S8). 
The median overall survival was 11.1 months in 
the ruxolitinib group and 6.5 months in the con-
trol group (hazard ratio for death, 0.83; 95% CI, 
0.60 to 1.15) (Fig. S6 and Table S9).
Safety
Treatment discontinuation occurred in 111 of 
154 patients (72%) in the ruxolitinib group and 
in 132 of 155 (85%) in the control group; the most 
common reason was lack of efficacy (in 32 [21%] 
and 68 [44%], respectively). The median duration 
of exposure to therapy was 63 days (range, 6 to 
396) in the ruxolitinib group and 29 days (range, 









Median (range) — yr 52.5 (12–73) 54.0 (13–71) 54.0 (12–73)
12 to <18 yr — no. (%) 5 (3) 4 (3) 9 (3)
>65 yr — no. (%) 21 (14) 25 (16) 46 (15)
Male sex — no. (%) 92 (60) 91 (59) 183 (59)
Race — no. (%)‡
White 111 (72) 102 (66) 213 (69)
Black 0 1 (1) 1 (<1)
Asian 19 (12) 29 (19) 48 (16)
Other 8 (5) 4 (3) 12 (4)
Unknown 16 (10) 19 (12.3) 35 (11.3)
Median weight (range) — kg§ 67.7 (28.5–97.0) 66.2 (32.9–115.5) 67.0 (28.5–115.5)
Median body-mass index (range)¶ 23.3 (13.5–34.4) 22.5 (13.9–35.7) 23.1 (13.5–35.7)
*  The baseline characteristics of the patients were balanced between the two treatment groups. Percentages may not to-
tal 100 because of rounding.
†  Patients in the control group were to receive the investigator’s choice of therapy from a list of nine commonly used 
options: antithymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, 
mycophenolate mofetil, mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus), etanercept, or 
infliximab.
‡  Race was reported by patients or their guardians.
§  Data on weight were missing for 4 patients in the ruxolitinib group and for 3 in the control group (for 7 patients overall).
¶  The body-mass index is the weight in kilograms divided by the square of the height in meters. Data were missing for  
8 patients in the ruxolitinib group and for 13 in the control group (for 21 patients overall).
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1 to 188) in the control group. The median dose 
intensity of ruxolitinib was 16.8 mg per day (in-
terquartile range, 11.9 to 19.6).
A total of 152 patients in the ruxolitinib group 
and 150 in the control group received at least one 
dose of trial treatment. Adverse events developed 
in most patients in the two treatment groups (Ta-
ble 2). The most common events (of any grade and 
of grade ≥3) up to day 28 were thrombocytope-
nia, anemia, and cytomegalovirus infection (Ta-
ble 2). Infection of grade 3 severity up to day 28 
occurred in 34 patients (22%) who received rux-
olitinib and in 28 patients (19%) who received 
control therapy; the corresponding values at data 
cutoff were 56 patients (37%) and 42 patients 
(28%) (Tables S10 and S11). Among patients with 
infection, the median time to the first infection of 
grade 3 severity was 0.8 months with ruxolitinib, 
as compared with 0.7 months with control therapy; 
among all the patients (censoring data from pa-
tients without events by the Kaplan–Meier meth-
od), the median time to the first event was not 
reached in the ruxolitinib group, as compared with 
6.0 months in the control group. At the data-
cutoff date, 19 patients (12%) who had received 
ruxolitinib and 11 (7%) who had received control 
therapy had grade 3 or higher bleeding (hemor-
rhage), with serious adverse events being reported 
in 10 patients (7%) and 8 patients (5%), respec-
tively.
Serious adverse events up to day 28 occurred 
in 57 patients (38%) who had received ruxolitinib 
and in 51 patients (34%) who had received control 
therapy. Up to day 28, adverse events led to dose 
modifications in 58 patients (38%) who had re-
ceived ruxolitinib and 13 patients (9%) who had 
received control therapy and to treatment discon-
tinuation in 17 (11%) and 7 (5%), respectively. A 
total of 72 patients (47%) in the ruxolitinib group 
and 77 patients (51%) in the control group had 
died by the data-cutoff date, including 43 (28%) 
and 36 (24%), respectively, during the randomized 
treatment period (median duration of randomized 
treatment period, 63 days vs. 29 days). Most deaths 
were attributed to acute GVHD (34 patients [22%] 
in the ruxolitinib group and 37 [25%] in the con-
trol group). The most commonly reported causes 
of death were underlying disease progression, in-
cluding neoplasms (in 8 patients in the ruxolitinib 
group and 8 in the control group), multiple organ 
dysfunction syndrome (in 3 and 1, respectively), 
sepsis (in 4 and 3), and septic shock (in 3 and 3).
Discussion
Poor outcomes have been reported in patients who 
have glucocorticoid-refractory acute GVHD after 
allogeneic stem-cell transplantation.4,5,9,13 Little 
progress in the development of new treatments 
has been made in the past three decades.16,17 This 
randomized, phase 3 trial showed a significant 
improvement with a new therapy over standard 
care in patients with grade II to IV glucocorticoid-
refractory acute GVHD. Ruxolitinib therapy was 
associated with a significantly higher overall re-
sponse at day 28 than control therapy, and the 
durable overall response at day 56 was also sig-
Figure 2. Overall Response at Day 28 and Durable 
Overall Response at Day 56.
The primary end point was overall response (complete 
response or partial response) at day 28, and the key 
secondary end point was durable overall response at 
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nificantly higher in the ruxolitinib group than in 
the control group. Ruxolitinib therapy was also 
associated with a longer duration of response than 
control therapy and a longer failure-free survival. 
Overall survival data at this point (data cutoff at 
day 56) are not sufficiently mature to allow con-
clusions to be drawn regarding survival benefit. 
However, the percentage of patients who died 
from acute GVHD did not differ substantially 
between the groups.
The results of this trial support previously re-
ported findings with ruxolitinib in patients with 
glucocorticoid-refractory acute GVHD. In a retro-
spective, multicenter survey involving 54 patients, 
response (defined as the best response at any time 
point after starting ruxolitinib and before start-
ing a new drug) was 81.5%, including a complete 
response in 46.3% of the patients.23 In a prospec-
tive, phase 2 trial of ruxolitinib in patients with 
primarily grade III or IV acute GVHD (48% and 
20% of the patients, respectively), the response 
was 54.9% at day 28.24 On the basis of these re-
sults, the Food and Drug Administration (FDA) 
approved ruxolitinib for use in patients 12 years 
of age or older who had glucocorticoid-refractory 
acute GVHD.
Few randomized trials have evaluated therapies 
for glucocorticoid-refractory acute GVHD; no ther-
apy has been approved for this indication other 
than ruxolitinib, which was recently approved by 
the FDA. Trials evaluating the anti-CD147 antibody 
ABX-CBL (also called gavilimomab)17 or the anti-
CD25 antibody inolimomab16 did not show a sig-
nificant benefit as compared with standard care. 
Van Lint et al.12 found that adding antithymocyte 
globulin to methylprednisolone did not improve 
outcomes, and results with other combination 
regimens have not been promising.10,28 Given the 
variations in clinical practice, the current trial al-
lowed, at randomization, the investigator to select 
one of nine prespecified commonly used second-
line therapies in the control group, all of which are 
recommended by the European Society for Blood 
and Marrow Transplantation and the European 
LeukemiaNet.4 Although individual treatments 
have shown different efficacy results, the trial was 
designed to take this mixed pool of control thera-
pies into consideration, on the basis of a meta-
analysis by Martin et al.9
The safety profile of ruxolitinib in this trial 
was consistent with the known safety profile of 
ruxolitinib and was as expected in patients with 
glucocorticoid-refractory acute GVHD.23,24 Adverse 
events up to day 28 were mainly cytopenias, par-
ticularly thrombocytopenia and anemia. Although 
38% of the patients received modifications to the 
ruxolitinib dose, the percentage of patients who 
discontinued ruxolitinib owing to adverse events 
was 11%. The incidence of infection, which is par-
ticularly relevant in acute GVHD,29,30 was gener-
ally similar with ruxolitinib therapy and control 
Figure 3. Duration of Response and Failure-free Survival.
Competing risks were death without previous observation of progression 
of acute GVHD and the onset of chronic GVHD. The hazard ratio is for re-
lapse or progression of hematologic disease, non–relapse-related death, 
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Table 2. Most Frequent Adverse Events up to Day 28 (Safety Population).*
Event Ruxolitinib (N = 152) Control (N = 150)
Any Grade Grade ≥3 Any Grade Grade ≥3
number of patients (percent)
Any adverse event 145 (95) 118 (78) 140 (93) 117 (78)
Thrombocytopenia 50 (33) 41 (27) 27 (18) 23 (15)
Anemia 46 (30) 33 (22) 42 (28) 28 (19)
Cytomegalovirus infection† 39 (26) 11 (7) 31 (21) 12 (8)
Peripheral edema 28 (18) 2 (1) 26 (17) 1 (1)
Platelet count decreased 26 (17) 22 (14) 21 (14) 20 (13)
Neutropenia 24 (16) 20 (13) 19 (13) 14 (9)
Hypokalemia 20 (13) 9 (6) 25 (17) 9 (6)
Hypertension 16 (11) 9 (6) 14 (9) 6 (4)
Hypoalbuminemia 16 (11) 6 (4) 15 (10) 10 (7)
Pyrexia 16 (11) 2 (1) 17 (11) 2 (1)
Hypomagnesemia 15 (10) 0 20 (13) 1 (1)
Diarrhea 14 (9) 7 (5) 15 (10) 5 (3)
White-cell count decreased 14 (9) 11 (7) 13 (9) 11 (7)
Nausea 13 (9) 0 9 (6) 0
Hypocalcemia 12 (8) 3 (2) 10 (7) 4 (3)
Hypophosphatemia 12 (8) 5 (3) 14 (9) 7 (5)
Abdominal pain 11 (7) 4 (3) 7 (5) 2 (1)
Sepsis 11 (7) 10 (7) 6 (4) 5 (3)
Acute kidney injury 10 (7) 1 (1) 3 (2) 3 (2)
Alanine aminotransferase increased 10 (7) 3 (2) 10 (7) 4 (3)
Neutrophil count decreased 10 (7) 10 (7) 14 (9) 11 (7)
Vomiting 10 (7) 1 (1) 6 (4) 0
Epstein–Barr virus infection 9 (6) 0 8 (5) 3 (2)
Hyperglycemia 9 (6) 5 (3) 14 (9) 8 (5)
Hypogammaglobulinemia 9 (6) 2 (1) 5 (3) 0
Fall 8 (5) 1 (1) 1 (1) 0
Hyperkalemia 8 (5) 3 (2) 6 (4) 2 (1)
Hypotension 8 (5) 4 (3) 9 (6) 3 (2)
Leukopenia 8 (5) 7 (5) 2 (1) 2 (1)
Pancytopenia 8 (5) 7 (5) 6 (4) 5 (3)
Urinary tract infection 8 (5) 3 (2) 6 (4) 4 (3)
Gamma-glutamyltransferase increased 7 (5) 3 (2) 10 (7) 7 (5)
Pneumonia 6 (4) 5 (3) 8 (5) 7 (5)
Blood bilirubin increased 5 (3) 3 (2) 12 (8) 7 (5)
Pain in extremity 4 (3) 2 (1) 8 (5) 1 (1)
*  Shown are the adverse events that had an incidence of at least 5% in either group. The safety population included all 
patients who received at least one dose of trial therapy.
†  A distinction between cytomegalovirus infection and reactivation was not made in this trial.
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therapy, with infection of grade 3 severity occur-
ring in 22% and 19% of the patients, respectively. 
The incidence of cytomegalovirus infection was 
26% in the ruxolitinib group, which is higher than 
the 19.7% reported in a previous phase 2 trial 
involving 71 patients.24 However, it is in line with 
the incidence of cytomegalovirus reactivation ob-
served during a retrospective trial of ruxolitinib 
(33.3% and 14.6% among patients with glucocor-
ticoid-refractory acute GVHD and chronic GVHD, 
respectively23); a distinction between cytomega-
lovirus infection and reactivation was not made 
in the current trial. Mortality was similar in the 
two treatment groups, and in both groups the 
main causes of death were related to progression 
of either acute GVHD or cancer.
This trial showed that, among patients with 
grade II to IV glucocorticoid-refractory acute 
GVHD, ruxolitinib therapy led a significantly high-
er overall response than control therapy at day 28 
and a higher durable overall response at day 56. 
Patients receiving ruxolitinib had a higher inci-
dence of thrombocytopenia and modestly higher 
incidence of anemia, infection, and cytomegalo-
virus infection than those who received control 
therapy.
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